J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.BO)
INR 1941.8
(4.63%)
INR 1941.8
(4.63%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.52 Billion INR | 34.84% |
| 2022 | 4.09 Billion INR | 6.35% |
| 2021 | 3.85 Billion INR | -13.98% |
| 2020 | 4.47 Billion INR | 64.66% |
| 2019 | 2.72 Billion INR | 40.62% |
| 2018 | 1.93 Billion INR | 39.85% |
| 2017 | 1.38 Billion INR | -24.84% |
| 2016 | 1.84 Billion INR | 13.24% |
| 2015 | 1.62 Billion INR | 61.89% |
| 2014 | 1 Billion INR | 63.27% |
| 2013 | 614.95 Million INR | -22.59% |
| 2012 | 794.44 Million INR | -88.28% |
| 2011 | 6.77 Billion INR | 386.57% |
| 2010 | 1.39 Billion INR | 17.32% |
| 2009 | 1.18 Billion INR | 361.9% |
| 2008 | 257.09 Million INR | -43.27% |
| 2007 | 453.2 Million INR | -27.11% |
| 2006 | 621.77 Million INR | -11.48% |
| 2005 | 702.37 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.76 Billion INR | 40.17% |
| 2023 Q2 | 1.5 Billion INR | 5.81% |
| 2023 FY | 5.52 Billion INR | 34.84% |
| 2023 Q4 | 1.26 Billion INR | -5.55% |
| 2023 Q3 | 1.33 Billion INR | -11.3% |
| 2023 Q1 | 1.42 Billion INR | 62.43% |
| 2022 Q4 | 876.2 Million INR | -17.42% |
| 2022 Q1 | 1.05 Billion INR | 23.79% |
| 2022 FY | 4.09 Billion INR | 6.35% |
| 2022 Q2 | 1.11 Billion INR | 5.76% |
| 2022 Q3 | 1.06 Billion INR | -4.48% |
| 2021 Q1 | 1.18 Billion INR | 18.15% |
| 2021 Q4 | 848.45 Million INR | 1.15% |
| 2021 FY | 3.85 Billion INR | -13.98% |
| 2021 Q3 | 838.8 Million INR | -14.19% |
| 2021 Q2 | 977.5 Million INR | -17.77% |
| 2020 Q1 | 1.19 Billion INR | 138.18% |
| 2020 FY | 4.47 Billion INR | 64.66% |
| 2020 Q4 | 1 Billion INR | -34.71% |
| 2020 Q2 | 738.22 Million INR | -38.18% |
| 2020 Q3 | 1.54 Billion INR | 108.75% |
| 2019 Q3 | 662.77 Million INR | -29.21% |
| 2019 Q4 | 501.39 Million INR | -24.35% |
| 2019 Q2 | 936.24 Million INR | 50.99% |
| 2019 Q1 | 620.06 Million INR | 32.9% |
| 2019 FY | 2.72 Billion INR | 40.62% |
| 2018 Q1 | 456.25 Million INR | 0.0% |
| 2018 Q3 | 498.54 Million INR | -2.87% |
| 2018 FY | 1.93 Billion INR | 39.85% |
| 2018 Q4 | 466.57 Million INR | -6.41% |
| 2018 Q2 | 513.28 Million INR | 12.5% |
| 2017 Q1 | 203.67 Million INR | -51.68% |
| 2017 FY | 1.38 Billion INR | -24.84% |
| 2016 FY | 1.84 Billion INR | 13.24% |
| 2016 Q4 | 421.49 Million INR | 0.0% |
| 2015 Q4 | 505.36 Million INR | 0.0% |
| 2015 FY | 1.62 Billion INR | 61.89% |
| 2014 FY | 1 Billion INR | 63.27% |
| 2013 Q1 | 203.25 Million INR | 0.0% |
| 2013 FY | 614.95 Million INR | -22.59% |
| 2012 FY | 794.44 Million INR | -88.28% |
| 2012 Q1 | 43.08 Million INR | 0.0% |
| 2011 FY | 6.77 Billion INR | 386.57% |
| 2010 FY | 1.39 Billion INR | 17.32% |
| 2009 FY | 1.18 Billion INR | 361.9% |
| 2008 FY | 257.09 Million INR | -43.27% |
| 2007 FY | 453.2 Million INR | -27.11% |
| 2006 FY | 621.77 Million INR | -11.48% |
| 2005 FY | 702.37 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 8.16 Billion INR | 32.29% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -1128.81% |
| Sigachi Industries Limited | 571.8 Million INR | -866.467% |
| Bal Pharma Limited | 73.92 Million INR | -7375.823% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | -31.277% |
| Medico Remedies Limited | 82.9 Million INR | -6565.474% |
| Lasa Supergenerics Limited | -217.3 Million INR | 2643.086% |
| Venus Remedies Limited | 284.9 Million INR | -1839.671% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 242.719% |
| Alpa Laboratories Limited | 167.76 Million INR | -3194.059% |
| Nectar Lifesciences Limited | 49.95 Million INR | -10963.62% |
| Shilpa Medicare Limited | 318.74 Million INR | -1633.778% |
| Aarti Drugs Limited | 1.71 Billion INR | -222.386% |
| Lupin Limited | 19.14 Billion INR | 71.134% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 82.583% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 85.681% |
| Windlas Biotech Limited | 581.87 Million INR | -849.744% |
| Suven Life Sciences Limited | -1.05 Billion INR | 625.93% |
| Eris Lifesciences Limited | 3.91 Billion INR | -40.983% |
| Valiant Laboratories Limited | 3.19 Million INR | -172812.328% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 197.398% |
| Ipca Laboratories Limited | 5.47 Billion INR | -0.964% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -632.403% |
| Achyut Healthcare Limited | 5.73 Million INR | -96310.991% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 94.229% |
| Bajaj HealthCare Limited | -837.93 Million INR | 759.515% |
| RPG Life Sciences Limited | 876.6 Million INR | -530.422% |
| Mankind Pharma Limited | 19.12 Billion INR | 71.11% |
| Laurus Labs Limited | 1.6 Billion INR | -244.209% |
| Piramal Pharma Limited | 178.2 Million INR | -3001.166% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -2083.074% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 66.636% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 10.261% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 136.801% |
| Unichem Laboratories Limited | -704.74 Million INR | 884.155% |
| Sequent Scientific Limited | -358.69 Million INR | 1640.684% |
| Novartis India Limited | 851.9 Million INR | -548.7% |
| Wanbury Limited | 559.56 Million INR | -887.606% |
| Suven Pharmaceuticals Limited | 3 Billion INR | -84.037% |
| Wockhardt Limited | -4.63 Billion INR | 219.358% |
| Themis Medicare Limited | 435.23 Million INR | -1169.714% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -2360.169% |
| Jubilant Pharmova Limited | 771 Million INR | -616.768% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | -17.359% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 90.076% |
| Divi's Laboratories Limited | 16 Billion INR | 65.461% |
| NATCO Pharma Limited | 13.88 Billion INR | 60.194% |
| Gufic Biosciences Limited | 861.35 Million INR | -541.579% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | -311.09% |
| Ind-Swift Limited | 142.31 Million INR | -3783.186% |
| Procter & Gamble Health Limited | 2 Billion INR | -174.967% |
| FDC Limited | 3.05 Billion INR | -81.057% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 2901.179% |
| Granules India Limited | 4.05 Billion INR | -36.347% |
| Medicamen Biotech Limited | 109.31 Million INR | -4955.602% |
| Alkem Laboratories Limited | 17.95 Billion INR | 69.226% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | -242.163% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -77822.702% |
| Brooks Laboratories Limited | -195.91 Million INR | 2920.695% |
| Megasoft Limited | -127.46 Million INR | 4435.492% |
| ZIM Laboratories Limited | 172.46 Million INR | -3104.308% |
| Strides Pharma Science Limited | -706.14 Million INR | 882.604% |
| Neuland Laboratories Limited | 3 Billion INR | -84.161% |
| Morepen Laboratories Limited | 961.59 Million INR | -474.697% |
| Hikal Limited | 696.02 Million INR | -693.983% |
| Indoco Remedies Limited | 984.6 Million INR | -461.271% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | -154.782% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -3684.759% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 6191.778% |
| Hester Biosciences Limited | 188.89 Million INR | -2825.659% |